Liver Failure and Liver Disease

You have full text access to this OnlineOpen article

Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture†

  1. Christopher J. Scarlett1,‡,§,
  2. Alex J. Saxby1,‡,
  3. AiQun Nielsen1,
  4. Cameron Bell2,
  5. Jaswinder S. Samra1,
  6. Thomas Hugh1,
  7. Robert C. Baxter3,†,
  8. Ross C. Smith1,¶,†,*

Article first published online: 29 AUG 2006

DOI: 10.1002/hep.21294

Issue

Hepatology

Hepatology

Volume 44, Issue 3, pages 658–666, September 2006

Additional Information

How to Cite

Scarlett, C. J., Saxby, A. J., Nielsen, A., Bell, C., Samra, J. S., Hugh, T., Baxter, R. C. and Smith, R. C. (2006), Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology, 44: 658–666. doi: 10.1002/hep.21294

Author Information

  1. 1

    Department of Surgery, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia

  2. 2

    Department of Gastroenterology, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia

  3. 3

    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia

  1. †

    Potential conflict of interest: Dr. Baxter advises Tissue Therapies Pty Limited. Dr. Smith is chairman of, and received funding from, CanSur Pty Limited. He is also chairman of Mictocatheters Pty Limited.

  2. ‡

    Christopher J. Scarlett and Alex J. Saxby contributed equally to this study.

  3. §

    Scarlett is the recipient of a University of Sydney Postgraduate Award and is a Cancer Institute NSW Scholar.

  4. fax: (61) 2-9437-3522

*University of Sydney, Department of Surgery, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia

  1. †

    Potential conflict of interest: Dr. Baxter advises Tissue Therapies Pty Limited. Dr. Smith is chairman of, and received funding from, CanSur Pty Limited. He is also chairman of Mictocatheters Pty Limited.

  2. ‡

    Christopher J. Scarlett and Alex J. Saxby contributed equally to this study.

  3. §

    Scarlett is the recipient of a University of Sydney Postgraduate Award and is a Cancer Institute NSW Scholar.

  4. fax: (61) 2-9437-3522

Publication History

  1. Issue published online: 29 AUG 2006
  2. Article first published online: 29 AUG 2006
  3. Manuscript Accepted: 3 JUN 2006
  4. Manuscript Received: 6 DEC 2005

Funded by

  • Cure Cancer Australia Foundation
  • Cancer Surgery Research Foundation (CanSur)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (287K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Shintaro Kikkawa, Kazuyuki Sogawa, Mamoru Satoh, Hiroshi Umemura, Yoshio Kodera, Kazuyuki Matsushita, Takeshi Tomonaga, Masaru Miyazaki, Osamu Yokosuka, Fumio Nomura, Identification of a Novel Biomarker for Biliary Tract Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry, International Journal of Proteomics, 2012, 2012, 1

    CrossRef

  2. 2
    N S Sandanayake, J Sinclair, F Andreola, M H Chapman, A Xue, G J Webster, A Clarkson, A Gill, I D Norton, R C Smith, J F Timms, S P Pereira, A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures, British Journal of Cancer, 2011, 105, 9, 1370

    CrossRef

  3. You have open access to this content3
    Corinna Henkel, Kristina Schwamborn, Henning W. Zimmermann, Frank Tacke, Elisabeth Kühnen, Margarete Odenthal, M. Reid Groseclose, Richard M. Caprioli, Ralf Weiskirchen, From proteomic multimarker profiling to interesting proteins: thymosin-β4 and kininogen-1 as new potential biomarkers for inflammatory hepatic lesions, Journal of Cellular and Molecular Medicine, 2011, 15, 10
    Direct Link:
  4. 4
    Sridhar Rathinam, Aiman Alzetani, Jane Starczynski, Pala B. Rajesh, Stephen Nyangoma, Michael J. O. Wakelam, Nicholas D. James, Wenbin Wei, Lucinda J. Billingham, Philip J. Johnson, Ashley Martin, Douglas G. Ward, Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery, Clinical Proteomics, 2009, 5, 3-4, 148

    CrossRef

  5. 5
    Peter Findeisen, Michael Neumaier, Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective, Clinical Chemistry and Laboratory Medicine, 2009, 47, 6

    CrossRef

  6. 6
    Domenico Alvaro, Serum and bile biomarkers for cholangiocarcinoma, Current Opinion in Gastroenterology, 2009, 25, 3, 279

    CrossRef

  7. 7
    Ying Lin, William S. Dynan, Jeffrey R. Lee, Zhao-Hua Zhu, Robert R. Schade, The Current State of Proteomics in GI Oncology, Digestive Diseases and Sciences, 2009, 54, 3, 431

    CrossRef

  8. 8
    L. C. Whelan, K. A. R. Power, D. T. McDowell, J. Kennedy, W. M. Gallagher, Applications of SELDI-MS technology in oncology, Journal of Cellular and Molecular Medicine, 2008, 12, 5a
    Direct Link:
  9. 9
    Patrick Yachimski, Daniel S. Pratt, Cholangiocarcinoma, Journal of Clinical Gastroenterology, 2008, 42, 2, 178

    CrossRef

  10. 10
    Glenn K Bonney, Rachel A Craven, Raj Prasad, Alan F Melcher, Peter J Selby, Rosamonde E Banks, Circulating markers of biliary malignancy: opportunities in proteomics?, The Lancet Oncology, 2008, 9, 2, 149

    CrossRef

  11. 11
    Chiung-Yu Chen, Wei-Lun Tsai, Hui-Chun Wu, Mei-Jywan Syu, Cheng-Chung Wu, Shu-Chu Shiesh, Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis, Clinica Chimica Acta, 2008, 390, 1-2, 82

    CrossRef

  12. 12
    Ye-Sheng Wei, Yan-Hua Zheng, Wei-Bo Liang, Jian-Zhong Zhang, Zhi-Hui Yang, Mei-Li Lv, Jing Jia, Lin Zhang, Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis, Cancer, 2008, 112, 3
    Direct Link:
  13. 13
    Blanca Lumbreras, Miquel Porta, Soledad Márquez, Marina Pollán, Lucy A. Parker, Ildefonso Hernández-Aguado, QUADOMICS: An adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of ‘-omics’-based technologies, Clinical Biochemistry, 2008, 41, 16-17, 1316

    CrossRef

  14. 14
    Liyun Liu, Jianing Wang, Bo Liu, Songwei Dai, Xiaomin Wang, Junzhou Chen, Lingyun Huang, Xueyuan Xiao, Dacheng He, Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma, Journal of Cellular Biochemistry, 2008, 104, 3
    Direct Link:
  15. 15
    Samuel C. L. Kuo, Sivakumar Gananadha, Christopher J. Scarlett, Anthony Gill, Ross C. Smith, Sporadic Pancreatic Polypeptide Secreting Tumors (PPomas) of the Pancreas, World Journal of Surgery, 2008, 32, 8, 1815

    CrossRef

  16. 16
    Tushar Patel, Pankaj Singh, Cholangiocarcinoma: emerging approaches to a challenging cancer, Current Opinion in Gastroenterology, 2007, 23, 3, 317

    CrossRef

  17. 17
    Christopher J. Scarlett, Jaswinder S. Samra, AiQun Xue, Robert C. Baxter, Ross C. Smith, CLASSIFICATION OF PANCREATIC CYSTIC LESIONS USING SELDI-TOF MASS SPECTROMETRY, ANZ Journal of Surgery, 2007, 77, 8
    Direct Link:
  18. You have free access to this content18
    Current literature in mass spectrometry, Journal of Mass Spectrometry, 2007, 42, 5
    Direct Link:
  19. 19
    Joseph S.K. Au, William C.S. Cho, Tai Tung Yip, Christine Yip, Hailong Zhu, Wallace W.F. Leung, Philip Y.B. Tsui, Davy L.P. Kwok, Simon S.M. Kwan, Wai Wai Cheng, Lawrence C.H. Tzang, Mengsu Yang, Stephen C.K. Law, Deep proteome profiling of sera from never-smoked lung cancer patients, Biomedicine & Pharmacotherapy, 2007, 61, 9, 570

    CrossRef

  20. 20
    Shuji Kanmura, Hirofumi Uto, Kazunori Kusumoto, Yoichi Ishida, Satoru Hasuike, Kenji Nagata, Katsuhiro Hayashi, Akio Ido, Sherri Oliver Stuver, Hirohito Tsubouchi, Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system, Hepatology, 2007, 45, 4
    Direct Link:
View Full Article (HTML) Get PDF (287K)